DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Ovide (Malathion Topical) - Summary

 
 



OVIDE SUMMARY

OVIDE Lotion contains 0.005 g of malathion per mL in a vehicle of isopropyl alcohol (78%), terpineol, dipentene, and pine needle oil. Malathion is an organophosphate agent which acts as a pediculicide by inhibiting cholinesterase activity.

OVIDE Lotion is indicated for patients infected with Pediculus humanus capitis (head lice and their ova) of the scalp hair.


See all Ovide indications & dosage >>

NEWS HIGHLIGHTS

Media Articles Related to Ovide (Malathion Topical)

New immunological findings provide possible therapy for cardiovascular disease
Source: Immune System / Vaccines News From Medical News Today [2014.11.17]
A new immunological mechanism in atherosclerosis and cardiovascular disease has been presented in a study from Karolinska Institutet in Sweden.

Study finds mental health providers not well prepared to care for military veterans
Source: Anxiety / Stress News From Medical News Today [2014.11.14]
Most community-based mental health providers are not well prepared to take care of the special needs of military veterans and their families, according to a new study by the RAND Corporation that was...

Single-dose, needle-free Ebola vaccine provides long-term protection in macaques
Source: Immune System / Vaccines News From Medical News Today [2014.11.14]
Scientists have demonstrated for the first time that a single-dose, needleless Ebola vaccine given to primates through their noses and lungs protected them against infection for at least 21 weeks.

Clinicians provide first successful delivery of dialysis in Ebola virus disease
Source: Urology / Nephrology News From Medical News Today [2014.11.14]
Acute kidney injury occurs frequently in Ebola virus disease; however, providing hemodialysis to these patients was previously thought to be too risky because it involves large needles or catheters...

Help in lung cancer staging and treatment decisions provided by risk stratification model
Source: Lung Cancer News From Medical News Today [2014.11.10]
A risk stratification model based on lymph node characteristics confirms with a high level of confidence the true lack of lung cancer in lymph nodes adequately sampled with endobronchial...

more news >>

Published Studies Related to Ovide (Malathion Topical)

Oral ivermectin for head lice: a comparison with 0.5 % topical malathion lotion. [2010.12]
BACKGROUND: Reports of treatment failure of head lice have become increasingly common. Oral ivermectin has been proposed as a potential alternative for the treatment of head lice infestation. The aim of this study was to compare the efficacy of oral ivermectin with topical malathion lotion in the treatment of head lice... CONCLUSIONS: Oral ivermectin is a promising effective approach for the treatment of head lice and could be an ideal substitute for conventional pediculicides. (c) The Author * Journal compilation (c) Blackwell Verlag GmbH, Berlin.

Oral ivermectin versus malathion lotion for difficult-to-treat head lice. [2010.03.11]
BACKGROUND: Head-lice infestation is prevalent worldwide, especially in children 3 to 11 years old. Topical insecticides (i.e., pyrethroids and malathion) used as a lotion, applied twice at an interval of 7 to 11 days, are typically used for treatment. Resistance of lice to insecticides, particularly pyrethroids, results in treatment failure. The efficacy of alternative agents is controversial... CONCLUSIONS: For difficult-to-treat head-lice infestation, oral ivermectin, given twice at a 7-day interval, had superior efficacy as compared with topical 0.5% malathion lotion, a finding that suggests that it could be an alternative treatment. (ClinicalTrials.gov number, NCT00819520.) 2010 Massachusetts Medical Society

Randomised, controlled, assessor blind trial comparing 4% dimeticone lotion with 0.5% malathion liquid for head louse infestation. [2007.11.07]
BACKGROUND: Malathion 0.5% has been the most prescribed pediculicide in the United Kingdom for around 10 years, and is widely used in Europe and North America...

Efficacy of a reduced application time of Ovide lotion (0.5% malathion) compared to Nix creme rinse (1% permethrin) for the treatment of head lice. [2004.11]
Our objective was to conduct a randomized, investigator-blinded evaluation of the pediculicidal and ovicidal activity of a reduced application time (20 minutes) of Ovide (0.5% malathion) compared to Nix (1% permethrin) in a south Florida population infested with Pediculus humanus capitis...

Oral ivermectin for head lice: a comparison with 0.5 % topical malathion lotion. [2010.08.13]
Summary Background: Reports of treatment failure of head lice have become increasingly common...

more studies >>

Clinical Trials Related to Ovide (Malathion Topical)

Safety and Efficacy of a Novel Malathion Formulation in the Treatment of Head Lice [Completed]
Current treatments for head lice include over-the-counter products such as permethrin and prescription products such as OVIDE (malathion 0. 5%) lotion. In a previous phase II study, a novel, easy-to-use malathion 0. 5% formulation was found to be a safe treatment for head lice. The current study will compare the efficacy and safety of this novel formulation of malathion with OVIDE and with an over-the-counter permethrin product.

Safety and Tolerability of a Novel Malathion Formulation in Children Age 6-24 Months With Head Lice [Recruiting]
In a previous phase II study, the safety and efficacy of a novel formulation of malathion 0. 5% was evaluated in patients 2 years of age and older. Based on the results of that study, this formulation is currently in a phase III study for that population.

The current study will use blood markers and clinical evaluations to determine the safety and tolerability of this formulation when used in children 6-24 months of age.

Efficacy, Safety and Tolerability of a Novel Malathion Formulation in Patients 2 Years and Older With Head Lice [Recruiting]
In this study, Malathion Gel 0. 5% will be compared to Nix (permethrin 1%) as a treatment for head lice in patients 2 years of age and older. Malathion Gel 0. 5% is a new formulation of an established head lice treatment. The new formulation has been evaluated in 2 previous studies of patients 2 years of age and older.

Efficacy, Safety and Tolerability of a Novel Malathion Formulation in Patients 2 Years and Older With Head Lice [Recruiting]
In this study, Malathion Gel 0. 5% will be compared to Nix (permethrin 1%) as a treatment for head lice in patients 2 years of age and older. Malathion Gel 0. 5% is a new formulation of an established head lice treatment. The new formulation has been evaluated in 2 previous studies of patients 2 years of age and older.

Safety and Tolerability of a Novel Malathion Formulation in Infants and Toddlers With Head Lice [Terminated]
In a previous phase II study, the safety and efficacy of a novel formulation of malathion 0. 5% was evaluated in patients 2 years of age and older. Based on the results of that study, this formulation is currently in a phase III study for that population.

The current study will use blood markers and clinical evaluations to determine the safety and tolerability of this formulation when used in children 6-24 months of age.

more trials >>

Reports of Suspected Ovide (Malathion Topical) Side Effects

Application Site Burn (3)Burns Second Degree (3)Fall (2)Loss of Consciousness (2)Skin Infection (2)Accidental Exposure (2)Chemical Injury (2)Muscle Atrophy (1)Peroneal Nerve Palsy (1)Oedema Peripheral (1)more >>


Page last updated: 2014-11-17

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2014